Printer Friendly
The Free Library
14,799,441 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Allergan Acquires Frumtost Pharmaceuticals.


IRVINE, Calif.--(BUSINESS WIRE)--June 13, 1995--Allergan-Lok Productos Farmaceutcos Ltda., has purchased all of the shares of the Brazilian company, Laboratorios Frumtost SA Industrias Farmaceuticas, for an undisclosed amount.

Allergan-Lok is a subsidiary of Allergan, Inc. (NYSE NYSE

See: New York Stock Exchange
:AGN AGN Again (Amateur Radio)
AGN Active Galactic Nucleus
AGN Acute Glomerulonephritis
AGN Accountants Global Network
AGN Air Gabon (ICAO code) 
), and has been operating in Brazil for 25 years in the eye-care market.

Frumtost has a product portfolio that encompasses ophthalmologic products as well as medications directed toward otorhinolaryngology otorhinolaryngology /oto·rhi·no·lar·yn·gol·o·gy/ (-ri?no-lar?ing-gol´ah-je) the branch of medicine dealing with the ear, nose, and throat.

o·to·rhi·no·lar·yn·gol·o·gy
n.
 and general medicine (aimed at treating allergies, inflammations, hypoglycemia hypoglycemia: see diabetes.
hypoglycemia

Below-normal levels of blood glucose, quickly reversed by administration of oral or intravenous glucose. Even brief episodes can produce severe brain dysfunction.
, triglycarides, coughs and colds, among other conditions).

Targeted investments in Latin America are part of Allergan's global expansion strategy, which has included two recently completed significant acquisitions in Argentina.

"The acquisition of Frumtost illustrates our commitment to customers and patients through eye-care product expansion around the world," said Allergan President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board.  William C. Shepherd. "By expanding our product line with the combination of ophthalmology, otorhinolaryngology and general medicine products, we are able to provide leading-edge technology to better serve the people of Brazil."

"Allergan's global resources and infrastructure will strengthen Frumtost's diverse product line, and supplement Allergan's focus on expanding its health-care presence in Brazil," said Carlos Zalduondo, managing director of Allergan-Lok Productos Farmaceutcos Ltda. "Obviously, this investment reflects Allergan's confidence in Brazil's future and the combination of Frumtost and Allergan-Lok will increase development and career opportunities for the employees of both companies."

Allergan, Inc. a global health care company headquartered in Irvine, California, develops, manufactures, and markets specialty therapeutic products for eye and skin care and neuromuscular neuromuscular /neu·ro·mus·cu·lar/ (-mus´ku-ler) pertaining to nerves and muscles, or to the relationship between them.

neu·ro·mus·cu·lar
adj.
1.
 disorders. A technology-driven company, Allergan is working to be the partner of choice for ever better health care.

CONTACT: Allergan, Irvine

Jeff D'Eliscu, 714/246-4636 (work)

714/675-9475 (home) REPEATS: New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
 212-575-8822 or 800-221-2462; Boston 617-330-5311 or

80
COPYRIGHT 1995 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1995, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 13, 1995
Words:284
Previous Article:FlexiInternational Announces Major Upgrade to its Entire Suite of Client/Server Financial Applications; New FlexiFinancials Offers Enterprises...
Next Article:IVAC names H. Clark Adams vice president of marketing and business development.
Topics:



Related Articles
Allergan and Ligand form new research and development corporation to raise $100 million; File unit offering for $32.5 million.
Allergan Ligand Retinoid Therapeutics, Inc. Subscription Offering Declared Effective By SEC.
Allergan reports 13 percent growth; board of directors declares quarterly dividend.
Allergan reports 13 percent sales growth for the year; board of directors declares quarterly dividend.
Ligand and Allergan Announce Buyout of Allergan Ligand Retinoid Therapeutics Inc.
Allergan and Dura Pharmaceuticals Enter Into Segment Alliance Agreement to Promote Multiple Products.
ALLERGAN LICENSES QUINOLONE ANTIBIOTIC FROM KYORIN.
Pyott's Voyage in Lilliput.(David E.I. Pyott, chief executive of Allergan)
Allergan, Inc. Exercises Option to Purchase Class A Common Stock of Allergan Specialty Therapeutics, Inc.
ALLERGAN, UPJOHN END MERGER TALKS.(BUSINESS)

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles